Bristol-Myers Squibb ROE 2006-2018 | BMY

Current and historical return on equity (ROE) values for Bristol-Myers Squibb (BMY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Bristol-Myers Squibb ROE for the three months ending September 30, 2018 was 47.89%.
Bristol-Myers Squibb ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $1.43B $13.75B 11.25%
2018-06-30 $0.38B $12.42B 2.89%
2018-03-31 $0.92B $12.91B 6.75%
2017-12-31 $1.01B $11.85B 7.18%
2017-09-30 $4.23B $14.91B 27.91%
2017-06-30 $4.59B $14.82B 29.84%
2017-03-31 $4.84B $14.54B 31.33%
2016-12-31 $4.46B $16.35B 28.87%
2016-09-30 $3.37B $15.78B 22.50%
2016-06-30 $2.87B $15.08B 19.35%
2016-03-31 $1.57B $14.55B 10.57%
2015-12-31 $1.57B $14.42B 10.32%
2015-09-30 $1.78B $15.27B 11.59%
2015-06-30 $1.79B $15.29B 11.71%
2015-03-31 $2.25B $15.69B 14.71%
2014-12-31 $2.00B $14.98B 13.12%
2014-09-30 $2.72B $15.20B 17.72%
2014-06-30 $2.69B $15.38B 17.67%
2014-03-31 $2.89B $15.53B 19.32%
2013-12-31 $2.56B $15.24B 17.67%
2013-09-30 $2.76B $14.71B 19.57%
2013-06-30 $1.36B $14.37B 9.77%
2013-03-31 $1.47B $13.70B 10.29%
2012-12-31 $1.96B $13.64B 13.15%
2012-09-30 $1.89B $13.90B 12.20%
2012-06-30 $3.56B $15.81B 22.14%
2012-03-31 $3.82B $16.25B 23.61%
2011-12-31 $3.70B $15.87B 23.01%
2011-09-30 $3.32B $16.44B 20.72%
2011-06-30 $3.30B $16.15B 20.80%
2011-03-31 $3.33B $15.90B 21.16%
2010-12-31 $3.09B $15.64B 19.84%
2010-09-30 $10.63B $15.86B 69.17%
2010-06-30 $10.64B $15.57B 71.00%
2010-03-31 $10.70B $15.23B 73.38%
2009-12-31 $10.59B $14.79B 75.37%
2009-09-30 $3.83B $14.37B 28.57%
2009-06-30 $5.44B $13.94B 41.70%
2009-03-31 $5.22B $13.13B 42.60%
2008-12-31 $5.25B $12.21B 45.15%
2008-09-30 $3.91B $12.94B 34.92%
2008-06-30 $2.19B $10.78B 20.38%
2008-03-31 $2.14B $10.56B 19.85%
2007-12-31 $2.17B $10.56B 20.26%
2007-09-30 $2.12B $11.15B 20.11%
2007-06-30 $1.60B $10.76B 15.02%
2007-03-31 $1.56B $10.26B 14.34%
2006-12-31 $1.59B $9.99B 14.14%
2006-09-30 $2.22B $11.59B 19.26%
2006-06-30 $2.84B $11.71B 24.87%
2006-03-31 $3.18B $11.56B 28.38%
2005-12-31 $3.00B $11.21B 27.49%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $86.637B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $390.174B 18.29
Pfizer (PFE) United States $261.450B 14.74
Merck (MRK) United States $206.852B 17.92
Novartis AG (NVS) Switzerland $201.155B 17.24
AbbVie (ABBV) United States $130.807B 11.61
Eli Lilly (LLY) United States $120.318B 21.15
Novo Nordisk (NVO) Denmark $110.887B 18.01
Sanofi (SNY) France $109.052B 13.50
AstraZeneca (AZN) United Kingdom $96.706B 12.01
GlaxoSmithKline (GSK) United Kingdom $92.502B 12.43